De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Theracryf Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Huw Jones

Algemeen directeur

UK£302.9k

Totale compensatie

Percentage CEO-salaris	71.0%
Dienstverband CEO	4yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	9yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Oct 11

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Nov 24

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Aug 06

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Apr 09

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Dec 25

Analyse CEO-vergoeding

Hoe is Huw Jones's beloning veranderd ten opzichte van Theracryf's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	UK£303k	UK£215k	-UK£3m
Dec 31 2023	n/a	n/a	-UK£3m
Sep 30 2023	n/a	n/a	-UK£3m
Jun 30 2023	n/a	n/a	-UK£4m
Mar 31 2023	UK£305k	UK£200k	-UK£4m
Dec 31 2022	n/a	n/a	-UK£4m
Sep 30 2022	n/a	n/a	-UK£3m
Jun 30 2022	n/a	n/a	-UK£3m
Mar 31 2022	UK£240k	UK£188k	-UK£3m
Dec 31 2021	n/a	n/a	-UK£3m
Sep 30 2021	n/a	n/a	-UK£2m
Jun 30 2021	n/a	n/a	-UK£3m
Mar 31 2021	UK£224k	UK£88k	-UK£3m

Compensatie versus markt: De totale vergoeding ($USD 402.25K ) Huw } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 373.18K ).

Compensatie versus inkomsten: De vergoeding van Huw is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Huw Jones (65 yo)

4yrs

Tenure

UK£302,890

Compensatie

Dr. Huw Jones, BSc, Ph D., serves as Non-Executive Director of Ixaka Limited since August 2023. He serves as Chief Executive Officer at Theracryf Plc (formerly known as Evgen Pharma plc) since October 1, 2...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Huw Jones	CEO & Executive Director	4yrs	UK£302.89k	0.75% £ 23.9k
Toni Haenninen	CFO & Director	1.1yrs	UK£385.25k	0.23% £ 7.5k
Helen Kuhlman	Chief Business Officer	3.5yrs	geen gegevens	0.25% £ 7.9k
Glen Clack	Chief Medical Officer	3.4yrs	geen gegevens	0.23% £ 7.5k

3.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van TCF wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Huw Jones	CEO & Executive Director	no data	UK£302.89k	0.75% £ 23.9k
Toni Haenninen	CFO & Director	less than a year	UK£385.25k	0.23% £ 7.5k
Susan Foden	Chair & Senior Independent Director	9.9yrs	UK£36.39k	0.17% £ 5.4k
Alan Barge	Independent Non-Executive Director	9yrs	UK£22.91k	geen gegevens

9.0yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TCF wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).

Theracryf Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Insufficient new directors

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Recent updates

New major risk - Share price stability

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024

New minor risk - Financial data availability

Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.

Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.

Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer

Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

New minor risk - Share price stability

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation Approved

New major risk - Market cap size

New minor risk - Share price stability

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Consensus revenue estimates fall by 92%

Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023

Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts Dosed

Consensus forecasts updated

Evgen Pharma plc to Report First Half, 2023 Results on Dec 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Clinical Trial Update

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Receives Regulatory and Ethical Approvals for A Healthy Volunteer, Pharmacokinetic and Pharmacodynamic, Study Toexamine the Performance of the Company's New Enteric Coated Tablet Formulation of Lead Asset SFX-01

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Evgen Pharma plc to Report Fiscal Year 2022 Results on Jun 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Progress Discussions with the UK Medicines and Healthcare Products Regulatory Agency and the US Food and Drug Administration

Insufficient new directors

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Announces Early Data for SFX-01 in Leukaemia Cell Lines

Evgen Pharma plc Announces Glioma Orphan Drug Application Submitted to US FDA

Evgen Pharma plc Announces Progress on Metastatic Breast Cancer Programme

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Evgen Pharma plc Provides Update on Data Safety Review for STAR COVID-19 Trial

Evgen Pharma plc Updates on Patient Recruitment

Evgen Pharma plc, Annual General Meeting, Mar 03, 2021

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Evgen Pharma plc to Report Fiscal Year 2020 Results on Jun 15, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd